Accessibility: Skip TopNav
Figure 2:
Percentage change in total tumour length, from baseline to 12-weeks, by patient (with RECIST 1.1 response designation).
Format
JPEG
Source
Noxopharm, Ltd.
Downloads
Original
Large
Medium
Small